Skip to main content
Fig. 10 | Cancer Cell International

Fig. 10

From: Deciphering the prognostic features of bladder cancer through gemcitabine resistance and immune-related gene analysis and identifying potential small molecular drug PIK-75

Fig. 10

RAC3 was higher expressed in GEM-resistant patients. A Representative images of IHC staining of RAC3 of tumor tissue from gemcitabine-sensitive (GEM-sensitive) or gemcitabine-resistant (GEM-resistant) patients. B Western blot analysis of RAC3 in T24 and 5637 after transfected with shNC or shRAC3. C qPCR analysis of the mRNA levels of RAC3 after transfected with shNC or shRAC3. D IC50 analysis of T24 and 5637 treated by gemcitabine. E Western blot analysis of RAC3 after PIK-75- or DMSO-treated. F qPCR analysis of the mRNA levels of RAC3 after PIK-75- or DMSO-treated

Back to article page

Cancer Cell International

ISSN: 1475-2867

Contact us